A Dallas, Texas based VC firm that was founded in 2011 and is focused on healthcare companies. The firm makes seed, venture, and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $100K to $1M per portfolio company. The firm generally acts as the lead investor and is open to investing in syndicates. The firm primarily invests in companies that are based in Texas but is open to opportunities across North America. The firm is actively seeking new investment opportunities.

The firm is currently seeking to invest in medical devices, diagnostics, digital health, and software. The firm is also interested in reformulated and repurposed drugs that have mitigated risk. For medical devices, the firm is opportunistic in terms of subsectors. Ideally, the product has a prototype and 510(k) regulatory pathway. The firm is open to investing in any indication, including orphan diseases; the dental field is of interest.

The firm seeks a strong and experienced management team. The firm may take a board seat where appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A newly founded investment firm based in Melbourne, Australia. The firm manages an open-ended, evergreen fund that focuses on life science investments. The firm invests in both early-stage and late-stage companies with a slight focus on the latter. In early-stage companies, the size of initial investment is between $1-5M. The firm is a provider of continuous capital and will continue to support portfolio companies through follow-on investments (provided milestones are met). The firm is open to global investments and does not require an Australia angle.

The firm invests broadly across the life sciences, including therapeutics, medical devices, diagnostics, digital health, and ag-bio, with 4 key investment themes that they closely navigate. The 4 themes are (1) personalized/precision medicine (i.e. NGS, big data), (2) infectious diseases and drug resistance (i.e. vaccines, anti-bacterials, rapid diagnostics), (3) “healthspan” (i.e. preventative and regenerative medicine, wellness, anything that slows the aging process, chronic diseases and age-related diseases), and (4) feeding the world (i.e. sustainable proteins, biological solutions for farmers, water and air purification technologies). The firm is stage agnostic and will consider technologies that are as early as pre-PoC.

The firm seeks to work with companies with innovative, highly disruptive technologies in the biotech/medical space. The firm is an active investor, meaning that the firm will work closely with portfolio companies to support their growth post-initial investment. The firm’s team has a broad range of experience in life sciences investments, funds management, international business development, etc., through which the firm provides strategic support. The firm prefers to lead and seek board representation, but this is not always the case.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A global firm with offices worldwide invests in medical technology companies that are strategically relevant to its parent company. The firm invests in new technologies via venture investing, collaborations, incubation, or M&A. The firm invests worldwide.

The firm’s primary focuses within healthcare include in-vitro diagnostics (particularly immuno and molecular diagnostics), digital lab services (including capacity management, care coordination, technologies that help physicians make diagnoses and other key decisions) and AI technologies in healthcare. The firm will invest in any medical indication area, and prefers companies that have at least attained proof of concept data or with a product on market demonstrating traction and revenue.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A cross-border venture capital firm with offices in USA and Asia is investing from a fund with its major LPs being large Asian pharmaceuticals. Typically the firm makes an initial investment ranging from under $1 million to $3-6 million dependent on the company’s stage of development. The firm can allocate up to $16 million over the lifetime of a company. The firm invests in early-stage therapeutic companies worldwide, with a focus on opportunities in North America.

The firm only invests in therapeutics, and are primarily focused on companies with preclinical or clinical assets. Within therapeutics, all modalities are of interest. The firm may invest up to 18 months prior to IND, however require that a company has a lead asset that has been characterized. The firm will consider opportunities in any indication area.

The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry. The firm only invests in companies with technology that has the potential to be first in class.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A micro VC fund founded by a group of alumni at an established university focuses on Angel to Series A stage companies across various sectors, including pharmaceutical, medical device and healthcare IT. The typical investment size is no more than $500,000, but the group will syndicate with other investors for larger investments. The firm looks to make investments in US companies with markets in US and/or China.

The firm is currently looking for new opportunities in the life science space. The fund is opportunistic in terms of sectors, subsectors and indications. The fund typically invests in seed round and series A round. Historically, the fund has been active in life science companies developing synthetic organelles-based research tools, nanoparticle research reagents and devices, web-based EMR system, proprietary screening and diagnostic tests for cancer, drug authentication platform and patient recovery technologies.

The firm focuses on investments in private companies and typically invests in prerevenue companies with strong and experienced management team. The firm will take a board seat or observer seat occasionally, depending on the investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm focuses on early-stage diagnostics, life science research tools, and biotech-related companies. The firm’s target initial investment size is $1-$2M. The firm prefers to act as the co-investor with other types of investors such as strategic partners. The firm invests in companies that are based in the US. The firm is actively seeking new investment opportunities.

In the life sciences, the firm is currently seeking to invest in early-stage diagnostics, life science research tools, and biotech-related companies. The firm will invest in a limited number of therapeutic opportunities. The firm also has interests in other technology fields. The firm is opportunistic in terms of subsectors and indications. The firm will consider investing in companies that have strong intellectual property protection and provide barriers to competitive entry. The firm also seeks companies with potential large addressable markets, which typically have the potential to generate at least $100M of annual revenues.

The firm seeks a reliable and experienced management team that can bring the concept to market. The firm may take a board seat in applicable cases. The firm aims fundraising CEOs that are driven to deliver exceptional investment returns to both investors and management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A fund that was initiated in 2001 by McKinsey & Company and the Swiss Federal Institute of Technology in Zürich. The firm invests the capital of 10 Swiss corporations, and invests in a variety of technological industries; about 50% of the firm’s portfolio companies are in the life science sector. The firm makes allocations from $500,000 to $10m over the life of the investment, and in the life science sector the firm’s allocations are typically over $5m. The firm only invests in companies based in Europe or with ties to Europe, and focuses on Switzerland and its surrounding region, including Germany, France and Austria.

The firm invests in the biotech and medtech sectors and is opportunistic within these sectors regarding indication area and technology. The firm prefers to invest in early-stage companies, with assets ranging from preclinical to mid-stage clinical trials (Phase II for therapeutics).

The firm prefers to invest in companies with ties to Switzerland, particularly those that use technology developed at a Swiss research institution, but will consider companies located in or with ties to the surrounding region. The firm seeks highly qualified, ambitious management teams, and is typically an activist investor that takes a seat on a portfolio company’s board.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.